• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 3 filed by new insider Labrucherie Gil M

    1/7/25 5:09:26 PM ET
    $SEPN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $SEPN alert in real time by email
    SEC FORM 3 SEC Form 3
    FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0104
    Estimated average burden
    hours per response: 0.5
    1. Name and Address of Reporting Person*
    Labrucherie Gil M

    (Last) (First) (Middle)
    SEPTERNA, INC.
    250 EAST GRAND AVENUE

    (Street)
    SOUTH SAN FRANCISCO CA 94080

    (City) (State) (Zip)
    2. Date of Event Requiring Statement (Month/Day/Year)
    01/06/2025
    3. Issuer Name and Ticker or Trading Symbol
    Septerna, Inc. [ SEPN ]
    4. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director 10% Owner
    X Officer (give title below) Other (specify below)
    Chief Financial Officer
    5. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Beneficially Owned
    1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
    Table II - Derivative Securities Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
    Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    Remarks:
    Exhibit 24 - Power of Attorney
    No securities are beneficially owned.
    /s/ Ran Xiao, Attorney-in-Fact 01/07/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $SEPN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SEPN

    DatePrice TargetRatingAnalyst
    2/18/2025$14.00Overweight → Equal Weight
    Wells Fargo
    11/19/2024$38.00Overweight
    Analyst
    11/19/2024Buy
    TD Cowen
    11/19/2024$43.00Overweight
    Wells Fargo
    11/19/2024$50.00Overweight
    Cantor Fitzgerald
    More analyst ratings

    $SEPN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • CEO and President Finer Jeffrey exercised 55,000 shares at a strike of $2.76, increasing direct ownership by 7% to 826,907 units (SEC Form 4)

      4 - Septerna, Inc. (0001984086) (Issuer)

      4/4/25 4:13:25 PM ET
      $SEPN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Ezekowitz Alan bought $92,270 worth of shares (13,319 units at $6.93), increasing direct ownership by 13% to 117,420 units (SEC Form 4)

      4 - Septerna, Inc. (0001984086) (Issuer)

      3/10/25 4:18:19 PM ET
      $SEPN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Ezekowitz Alan bought $515,934 worth of shares (86,681 units at $5.95), increasing direct ownership by 498% to 104,101 units (SEC Form 4)

      4 - Septerna, Inc. (0001984086) (Issuer)

      3/6/25 9:02:51 PM ET
      $SEPN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SEPN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Ezekowitz Alan bought $92,270 worth of shares (13,319 units at $6.93), increasing direct ownership by 13% to 117,420 units (SEC Form 4)

      4 - Septerna, Inc. (0001984086) (Issuer)

      3/10/25 4:18:19 PM ET
      $SEPN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Ezekowitz Alan bought $515,934 worth of shares (86,681 units at $5.95), increasing direct ownership by 498% to 104,101 units (SEC Form 4)

      4 - Septerna, Inc. (0001984086) (Issuer)

      3/6/25 9:02:51 PM ET
      $SEPN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CEO and President Finer Jeffrey bought $96,961 worth of shares (17,000 units at $5.70), increasing direct ownership by 2% to 771,907 units (SEC Form 4)

      4 - Septerna, Inc. (0001984086) (Issuer)

      2/27/25 6:53:01 PM ET
      $SEPN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SEPN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Septerna downgraded by Wells Fargo with a new price target

      Wells Fargo downgraded Septerna from Overweight to Equal Weight and set a new price target of $14.00

      2/18/25 8:55:10 AM ET
      $SEPN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Analyst initiated coverage on Septerna with a new price target

      Analyst initiated coverage of Septerna with a rating of Overweight and set a new price target of $38.00

      11/19/24 7:39:27 AM ET
      $SEPN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • TD Cowen initiated coverage on Septerna

      TD Cowen initiated coverage of Septerna with a rating of Buy

      11/19/24 7:39:11 AM ET
      $SEPN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SEPN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D filed by Septerna Inc.

      SC 13D - Septerna, Inc. (0001984086) (Subject)

      11/4/24 4:39:38 PM ET
      $SEPN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Septerna Inc.

      SC 13G - Septerna, Inc. (0001984086) (Subject)

      11/4/24 4:15:38 PM ET
      $SEPN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Septerna Inc.

      SC 13G - Septerna, Inc. (0001984086) (Subject)

      11/1/24 4:27:45 PM ET
      $SEPN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SEPN
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $SEPN
    SEC Filings

    See more
    • Septerna Provides Corporate Overview and Reports Fourth Quarter and Full Year 2024 Financial Results

      Preclinical Work Advancing with Plans to Select a Next-Generation Oral Small Molecule PTH1R Agonist to Accelerate Toward the Clinic Later This Year Phase 1 Trial for SEP-631, MRGPRX2 NAM Program for Mast Cell Diseases, Expected to Initiate in 2025 Well-Capitalized with $420.8M Balance Sheet as of YE 2024 to Support Operating Runway into Early 2028 SOUTH SAN FRANCISCO, Calif., March 27, 2025 (GLOBE NEWSWIRE) -- Septerna, Inc. (NASDAQ:SEPN), a biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today provided a corporate overview complete with upcoming milestones and reported fourth quarter and full year 2024 financial results. "Our Native Comp

      3/27/25 8:00:00 AM ET
      $SEPN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Septerna to Present at TD Cowen 45th Annual Health Care Conference

      SOUTH SAN FRANCISCO, Calif., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Septerna, Inc. (NASDAQ:SEPN), a biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today announced that Jeffrey Finer, M.D., Ph.D., Chief Executive Officer and Co-founder of Septerna, will present at the TD Cowen 45th Annual Health Care Conference on Wednesday, March 5, 2025, at 10:30 a.m. ET in Boston. About SepternaSepterna, Inc. is a biotechnology company pioneering a new era of GPCR drug discovery powered by its proprietary Native Complex Platform™. Its industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development

      2/26/25 8:00:00 AM ET
      $SEPN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Septerna Announces Discontinuation of SEP-786 Phase 1 Clinical Trial and Plans to Advance Next-Generation Oral Small Molecule PTH1R Agonist

      Trial decision follows unanticipated events of elevated unconjugated bilirubin levels Company advancing multiple next-generation PTH1R agonists with distinct and unrelated chemical structures relative to SEP-786 SOUTH SAN FRANCISCO, Calif., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Septerna, Inc. (NASDAQ:SEPN), a clinical-stage biotechnology company pioneering a new era of GPCR drug discovery, today announced its decision to discontinue the Phase 1 single- and multiple-ascending dose (SAD/MAD) clinical trial of SEP-786 in healthy volunteers. SEP-786 is an oral small molecule agonist of the parathyroid hormone 1 receptor (PTH1R) being developed for the treatment of hypoparathyroidism.

      2/18/25 8:00:00 AM ET
      $SEPN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by Septerna Inc.

      DEFA14A - Septerna, Inc. (0001984086) (Filer)

      4/29/25 4:08:35 PM ET
      $SEPN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEF 14A filed by Septerna Inc.

      DEF 14A - Septerna, Inc. (0001984086) (Filer)

      4/29/25 4:05:26 PM ET
      $SEPN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-8 filed by Septerna Inc.

      S-8 - Septerna, Inc. (0001984086) (Filer)

      3/27/25 8:51:02 AM ET
      $SEPN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SEPN
    Leadership Updates

    Live Leadership Updates

    See more
    • Septerna Expands Leadership with Appointment of Industry Veteran Gil Labrucherie as Chief Financial Officer

      SOUTH SAN FRANCISCO, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Septerna, Inc. (NASDAQ:SEPN), a clinical-stage biotech company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today announced the appointment of Gil Labrucherie, CFA, J.D., as Chief Financial Officer. Mr. Labrucherie is a seasoned biopharma executive with more than 25 years of senior leadership experience in finance and legal roles for public biopharmaceutical and technology companies. "We are excited to welcome Gil to the team," said Jeffrey Finer, M.D., Ph.D., Chief Executive Officer and Co-founder of Septerna. "His extensive expertise leading public company finance and capital strategy will be ins

      1/6/25 7:00:00 AM ET
      $SEPN
      Biotechnology: Pharmaceutical Preparations
      Health Care